We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 682.00 | 6.01% | 12,034.00 | 12,032.00 | 12,038.00 | 12,086.00 | 11,850.00 | 11,890.00 | 1,032,003 | 11:39:45 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 31.23 | 185.99B |
From Apr 2019 to Apr 2024
By Denise Roland
AstraZeneca PLC posted a loss in the second quarter as it furiously invested in its next-generation drugs while battling falling sales of its aging blockbuster Crestor, and took a restructuring charge relating to a cost-reduction program.
Cambridge, England-based Astra posted a net loss of $3 million in the three months to June 30, compared with a net profit of $697 million in the same period a year earlier. Revenue slipped 11% to $5.6 billion. Analysts expected net profit of $403 million and revenue of $5.6 billion.
Core operating profit, a measure which strips out one-time gains and losses, fell 22% to $1.4 billion, beating market expectations of $1.3 billion.
Astra's downbeat results were largely driven by a steep decline in sales of the company's cholesterol-lowering drug Crestor after a cheap copycat version launched in early May.
Write to Denise Roland at denise.roland@wsj.com
(END) Dow Jones Newswires
July 28, 2016 02:43 ET (06:43 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
